Human medicines European public assessment report (EPAR): DuoTrav, travoprost,timolol, Date of authorisation: 23/04/2006, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): DuoTrav, travoprost,timolol, Date of authorisation: 23/04/2006, Revision: 19, Status: Authorised

WHAT WOULD HELP ME IN IDENTIFYING AND MANAGING SARCOPENIA IN HOSPITALISED PATIENTS WITH MULTIMORBIDITY?

Dear EFIM Colleagues,

The Multimorbidity Working Group is developing Clinical Practice Guidelines for sarcopenia, focusing on the most relevant and pragmatic approaches for patients with multimorbidity.

To select the PICO questions, we highly value the invaluable input of clinicians who manage this issue daily.

We invite you to participate in a short 9-question survey designed to capture your insights and guide us in addressing key challenges in diagnosing and treating sarcopenia in in-patient clinical practice.

Contact details of national competent authorities for requests to use a sticker to place the Unique Identifier on the outer/immediate packaging of centrally approved products

Contact details of national competent authorities for requests to use a sticker to place the Unique Identifier on the outer/immediate packaging of centrally approved products

Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages

Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages

Joint HMA/EMA Big Data Steering Group workshop on real-world evidence (RWE) methods, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 June 2024, 09:00 (CEST) to 14 June 2024, 16:30 (CEST)

Joint HMA/EMA Big Data Steering Group workshop on real-world evidence (RWE) methods, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 June 2024, 09:00 (CEST) to 14 June 2024, 16:30 (CEST)

Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 12, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness